NCT01078662 - Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats | Biotech Hunter

Enrollment

298

Participants

Timeline

Start Date

February 21, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

August 12, 2024

Conditions

OvarianBreastProstatePancreaticAdvanced Tumours

Interventions

DRUG

olaparib

Tablets Oral BID

Trial Locations (14)

Research Site, Randwick

Research Site, Melbourne

Research Site, Philadelphia

Research Site, Haifa

Research Site, Haifa

Research Site, Petah Tikva

Research Site, Cologne

Research Site, Ramat Gan

Research Site, West Hollywood

Research Site, Jerusalem

Research Site, Jerusalem

Research Site, Tel Aviv

Research Site, Madrid

Research Site, Lund